Australia's most trusted
source of pharma news
Monday, 07 July 2025
Posted 4 July 2025 PM
News that AstraZeneca has pulled a long-standing breast cancer treatment from the Australian market was our top story this week.
The company confirmed that it initiated the process to cancel the registration of Faslodex in May 2025 noting equivalent therapeutic alternatives such as its generic fulvestrant are still registered in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.